Unpacking Circulate-JAPAN GALAXY data presented by Drs Kotaka and Yoshino. Takeaways: (1) ctDNA is most prognostic of recurrence (2) Tx of ctDNA (+) pts improves outcomes (3) can monitor response real-time to adjuvant tx. #GI22#ASCO#ctdna#Signatera#Naterapic.twitter.com/e8x9tzHKxh